High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy.

The letter to the editor in Leukemia & Lymphoma discusses the link between a high Ki67 index and shorter progression-free survival in patients with Follicular Lymphoma undergoing frontline immunochemotherapy. The study underscores the significance of Ki67 as a prognostic factor for evaluating the proliferative activity of lymphoma cells. Research conducted at two tertiary care medical centers revealed that an IF Ki67 index ≥ 30% was associated with an elevated risk of disease progression, emphasizing the necessity for further investigations to identify predictive baseline characteristics in Follicular Lymphoma. The study examined the correlation between FLIPI/Ki67 (FKi) score and progression-free survival (PFS) in FL patients receiving frontline immunochemotherapy, with the FKi score predicting an increased risk of progression and being linked to PFS. Despite limitations like a retrospective analysis and a small sample size, the study suggests the potential value of integrating Ki67 into prognostic indices for FL, calling for additional research to validate these findings and explore the incorporation of FLIPI and Ki67 in contemporary FL treatment protocols. [Extracted from the article]